A new phase II study of trastuzumab (Herceptin) and pertuzumab (Perjeta) added to neoadjuvant chemoradiotherapy (nCRT) followed by surgery in patients with esophageal adenocarcinoma (EAC) has found the combined regimen to be feasible and worthy of further study.
https://www.targetedonc.com/news/trastuzumab-plus-pertuzumab-added-to-standard-therapy-found-to-be-feasible-in-esophageal-cancer